Citation: 刘炜炜,葛春林. Castleman Disease. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2010, 17(8): 868-871. doi: Copy
1. | Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma [J]. Cancer, 1956; 9(4): 822830. |
2. | Keller AR, Hochholzer L, Castleman B. Hyalinevascular and plasmacell types of giant lymph node hyperplasia of the mediastinum and other locations [J]. Cancer, 1972; 29(3): 670683. |
3. | Gaba AR, Stein RS, Sweet DL, et al. Multicentric giant lymph node hyperplasia [J]. Am J Clin Pathol, 1978; 69(1): 8690. |
4. | Bowne WB, Lewis JJ, Filippa DA, et al. The management of unicentric and multicentric Castleman’s disease: a report of 16 cases and a review of the literature [J]. Cancer, 1999; 85(3): 706717. |
5. | Dispenzieri A. Castleman disease [J]. Cancer Treat Res, 2008; 142: 293330. |
6. | Cronin DM, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions [J]. Adv Anat Pathol, 2009; 16(4): 236246. |
7. | Wang H, Wieczorek RL, Zenilman ME, et al. Castleman’s disease in the head of the pancreas: report of a rare clinical entity and current perspective on diagnosis, treatment, and outcome [J]. World J Surg Oncol, 2007; 5: 133. |
8. | Kojima M, Nakamura S, Miyawaki S, et al. Progressive transformation of germinal center presenting with histological features of hyalinevascular type of Castleman’s disease [J]. APMIS, 2005; 113(4): 288295. |
9. | Roca B. Castleman’s disease. A review [J]. AIDS Rev, 2009; 11(1): 37. |
10. | McClain KL, Natkunam Y, Swerdlow SH. Atypical cellular disorders [J]. Hematology Am Soc Hematol Educ Program, 2004; 283296. |
11. | Hsu SM, Waldron JA, Xie SS, et al. Expression of interleukin6 in Castleman’s disease [J]. Hum Pathol, 1993; 24(8): 833839. |
12. | Bucher P, Chassot G, Zufferey G, et al. Surgical management of abdominal and retroperitoneal Castleman’s disease [J]. World J Surg Oncol, 2005; 3: 33. |
13. | Dispenzieri A, Gertz MA. Treatment of Castleman’s disease [J]. Curr Treat Options Oncol, 2005; 6(3): 255266. |
14. | Chan AC, Chan KW, Chan JK, et al. Development of follicular dendritic cell sarcoma in hyalinevascular Castleman’s disease of the nasopharynx: tracing its evolution by sequential biopsies [J]. Histopathology, 2001; 38(6): 510518. |
15. | Waterston A, Bower M. Fifty years of multicentric Castleman’s disease [J]. Acta Oncol, 2004; 43(8): 698704. |
16. | 黄小兵, 李靖, 梁平, 等. 腹膜后血管滤泡增生症的诊断治疗(附3例报道) [J]. 中国普外基础与临床杂志, 2005; 12(1): 7980. |
17. | Fields S, BarZiv J, Portnoy O, et al. Radiologic spectrum of localized Castleman’s disease [J]. Isr J Med Sci, 1995; 31(11): 660669. |
18. | Takihara H, Yamakawa G, Baba Y, et al. Castleman disease. Unusual retroperitoneal location indistinguishable from malignant tumor in preoperative angiographic appearance [J]. Urology, 1993; 41(2): 162164. |
19. | Murphy SP, Nathan MA, Karwal MW. FDGPET appearance of pelvic Castleman’s disease [J]. J Nucl Med, 1997; 38(8): 12111212. |
20. | Enomoto K, Nakamichi I, Hamada K, et al. Unicentric and multicentric Castleman’s disease [J]. Br J Radiol, 2007; 80(949): e24e26. |
21. | Oida Y, Shimizu K, Mukai M, et al. FDGPET and diffusionweighted MR imaging appearance in retroperitoneal Castleman’s disease: a case report [J]. Clin Imaging, 2008; 32(2): 144146. |
22. | Halac M, Ergul N, Sager S, et al. PET/CT findings in a multicentric form of Castleman’s disease [J]. Hell J Nucl Med, 2007; 10(3): 172174. |
23. | Frizzera G. Castleman’s disease and related disorders [J]. Semin Diagn Pathol, 1988; 5(4): 346364. |
24. | Maruyama S, Hao N, Cheng J, et al. Castleman’s disease of the buccal mucosa: report of a case and review of the literature of head and neck cases [J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2002; 93(3): 305310. |
25. | Weisenburger DD, Nathwani BN, Winberg CD, et al. Multicentric angiofollicular lymph node hyperplasia: a clinicopathologic study of 16 cases [J]. Hum Pathol, 1985; 16(2): 162172. |
26. | Shahidi H, Myers JL, Kvale PA. Castleman’s disease [J]. Mayo Clin Proc, 1995; 70(10): 969977. |
27. | Kiguchi H, Ishii T, Ishikawa Y, et al. Castleman’s disease of the abdomen and pelvis: report of three cases and a review of the literature [J]. J Gastroenterol, 1995; 30(5): 661666. |
28. | 罗友军. 腹膜后Castleman病1例报告 [J]. 中国普外基础与临床杂志, 2005; 12(3): 279. |
29. | Dham A, Peterson BA. Castleman disease [J]. Curr Opin Hematol, 2007; 14(4): 354359. |
30. | Gérard L, Bérezné A, Galicier L, et al. Prospective study of rituximab in chemotherapydependent human immunodeficiency virus associated multicentric Castleman’s disease: ANRS 117 CastlemaB Trial [J]. J Clin Oncol, 2007; 25(22): 33503356. |
31. | Bower M, Powles T, Williams S, et al. Brief communication: rituximab in HIVassociated multicentric Castleman disease [J]. Ann Intern Med, 2007; 147(12): 836839. |
32. | Seliem RM, Griffith RC, Harris NL, et al. HHV8+, EBV+ multicentric plasmablastic microlymphoma in an HIV+ Man: the spectrum of HHV8+ lymphoproliferative disorders expands [J]. Am J Surg Pathol, 2007; 31(9): 14391445. |
33. | Simonelli C, Tedeschi R, Gloghini A, et al. Plasma HHV8 viral load in HHV8related lymphoproliferative disorders associated with HIV infection [J]. J Med Virol, 2009; 81(5): 888896. |
34. | Guihot A, Oksenhendler E, Galicier L, et al. Multicentric Castleman disease is associated with polyfunctional effector memory HHV8specific CD8+ T cells [J]. Blood, 2008; 111(3): 13871395. |
35. | Nishimoto N, Terao K, Mima T, et al. Mechanisms and pathologic significances in increase in serum interleukin6 (IL6) and soluble IL6 receptor after administration of an antiIL6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease [J]. Blood, 2008; 112(10): 39593964. |
36. | Menke DM, Chadbum A, Cesarman E, et al. Analysis of the human herpesvirus 8 (HHV8) genome and HHV8 vIL6 expression in archival cases of castleman disease at low risk for HIV infection [J]. Am J Clin Pathol, 2002; 117(2): 268275. |
37. | Matsuyama M, Suzuki T, Tsuboi H, et al. Antiinterleukin6 receptor antibody (tocilizumab) treatment of multicentric Castleman’s disease [J]. Intern Med, 2007; 46(11): 771774. |
38. | Scott D, Cabral L, Harrington WJ Jr. Treatment of HIVassociated multicentric Castleman’s disease with oral etoposide [J]. Am J Hematol, 2001; 66(2): 148150. |
39. | Kumari P, Schechter GP, Saini N, et al. Successful treatment of human immunodeficiency virusrelated Castleman’s disease with interferonα [J]. Clin Infect Dis, 2000; 31(2): 602604. |
- 1. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma [J]. Cancer, 1956; 9(4): 822830.
- 2. Keller AR, Hochholzer L, Castleman B. Hyalinevascular and plasmacell types of giant lymph node hyperplasia of the mediastinum and other locations [J]. Cancer, 1972; 29(3): 670683.
- 3. Gaba AR, Stein RS, Sweet DL, et al. Multicentric giant lymph node hyperplasia [J]. Am J Clin Pathol, 1978; 69(1): 8690.
- 4. Bowne WB, Lewis JJ, Filippa DA, et al. The management of unicentric and multicentric Castleman’s disease: a report of 16 cases and a review of the literature [J]. Cancer, 1999; 85(3): 706717.
- 5. Dispenzieri A. Castleman disease [J]. Cancer Treat Res, 2008; 142: 293330.
- 6. Cronin DM, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions [J]. Adv Anat Pathol, 2009; 16(4): 236246.
- 7. Wang H, Wieczorek RL, Zenilman ME, et al. Castleman’s disease in the head of the pancreas: report of a rare clinical entity and current perspective on diagnosis, treatment, and outcome [J]. World J Surg Oncol, 2007; 5: 133.
- 8. Kojima M, Nakamura S, Miyawaki S, et al. Progressive transformation of germinal center presenting with histological features of hyalinevascular type of Castleman’s disease [J]. APMIS, 2005; 113(4): 288295.
- 9. Roca B. Castleman’s disease. A review [J]. AIDS Rev, 2009; 11(1): 37.
- 10. McClain KL, Natkunam Y, Swerdlow SH. Atypical cellular disorders [J]. Hematology Am Soc Hematol Educ Program, 2004; 283296.
- 11. Hsu SM, Waldron JA, Xie SS, et al. Expression of interleukin6 in Castleman’s disease [J]. Hum Pathol, 1993; 24(8): 833839.
- 12. Bucher P, Chassot G, Zufferey G, et al. Surgical management of abdominal and retroperitoneal Castleman’s disease [J]. World J Surg Oncol, 2005; 3: 33.
- 13. Dispenzieri A, Gertz MA. Treatment of Castleman’s disease [J]. Curr Treat Options Oncol, 2005; 6(3): 255266.
- 14. Chan AC, Chan KW, Chan JK, et al. Development of follicular dendritic cell sarcoma in hyalinevascular Castleman’s disease of the nasopharynx: tracing its evolution by sequential biopsies [J]. Histopathology, 2001; 38(6): 510518.
- 15. Waterston A, Bower M. Fifty years of multicentric Castleman’s disease [J]. Acta Oncol, 2004; 43(8): 698704.
- 16. 黄小兵, 李靖, 梁平, 等. 腹膜后血管滤泡增生症的诊断治疗(附3例报道) [J]. 中国普外基础与临床杂志, 2005; 12(1): 7980.
- 17. Fields S, BarZiv J, Portnoy O, et al. Radiologic spectrum of localized Castleman’s disease [J]. Isr J Med Sci, 1995; 31(11): 660669.
- 18. Takihara H, Yamakawa G, Baba Y, et al. Castleman disease. Unusual retroperitoneal location indistinguishable from malignant tumor in preoperative angiographic appearance [J]. Urology, 1993; 41(2): 162164.
- 19. Murphy SP, Nathan MA, Karwal MW. FDGPET appearance of pelvic Castleman’s disease [J]. J Nucl Med, 1997; 38(8): 12111212.
- 20. Enomoto K, Nakamichi I, Hamada K, et al. Unicentric and multicentric Castleman’s disease [J]. Br J Radiol, 2007; 80(949): e24e26.
- 21. Oida Y, Shimizu K, Mukai M, et al. FDGPET and diffusionweighted MR imaging appearance in retroperitoneal Castleman’s disease: a case report [J]. Clin Imaging, 2008; 32(2): 144146.
- 22. Halac M, Ergul N, Sager S, et al. PET/CT findings in a multicentric form of Castleman’s disease [J]. Hell J Nucl Med, 2007; 10(3): 172174.
- 23. Frizzera G. Castleman’s disease and related disorders [J]. Semin Diagn Pathol, 1988; 5(4): 346364.
- 24. Maruyama S, Hao N, Cheng J, et al. Castleman’s disease of the buccal mucosa: report of a case and review of the literature of head and neck cases [J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2002; 93(3): 305310.
- 25. Weisenburger DD, Nathwani BN, Winberg CD, et al. Multicentric angiofollicular lymph node hyperplasia: a clinicopathologic study of 16 cases [J]. Hum Pathol, 1985; 16(2): 162172.
- 26. Shahidi H, Myers JL, Kvale PA. Castleman’s disease [J]. Mayo Clin Proc, 1995; 70(10): 969977.
- 27. Kiguchi H, Ishii T, Ishikawa Y, et al. Castleman’s disease of the abdomen and pelvis: report of three cases and a review of the literature [J]. J Gastroenterol, 1995; 30(5): 661666.
- 28. 罗友军. 腹膜后Castleman病1例报告 [J]. 中国普外基础与临床杂志, 2005; 12(3): 279.
- 29. Dham A, Peterson BA. Castleman disease [J]. Curr Opin Hematol, 2007; 14(4): 354359.
- 30. Gérard L, Bérezné A, Galicier L, et al. Prospective study of rituximab in chemotherapydependent human immunodeficiency virus associated multicentric Castleman’s disease: ANRS 117 CastlemaB Trial [J]. J Clin Oncol, 2007; 25(22): 33503356.
- 31. Bower M, Powles T, Williams S, et al. Brief communication: rituximab in HIVassociated multicentric Castleman disease [J]. Ann Intern Med, 2007; 147(12): 836839.
- 32. Seliem RM, Griffith RC, Harris NL, et al. HHV8+, EBV+ multicentric plasmablastic microlymphoma in an HIV+ Man: the spectrum of HHV8+ lymphoproliferative disorders expands [J]. Am J Surg Pathol, 2007; 31(9): 14391445.
- 33. Simonelli C, Tedeschi R, Gloghini A, et al. Plasma HHV8 viral load in HHV8related lymphoproliferative disorders associated with HIV infection [J]. J Med Virol, 2009; 81(5): 888896.
- 34. Guihot A, Oksenhendler E, Galicier L, et al. Multicentric Castleman disease is associated with polyfunctional effector memory HHV8specific CD8+ T cells [J]. Blood, 2008; 111(3): 13871395.
- 35. Nishimoto N, Terao K, Mima T, et al. Mechanisms and pathologic significances in increase in serum interleukin6 (IL6) and soluble IL6 receptor after administration of an antiIL6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease [J]. Blood, 2008; 112(10): 39593964.
- 36. Menke DM, Chadbum A, Cesarman E, et al. Analysis of the human herpesvirus 8 (HHV8) genome and HHV8 vIL6 expression in archival cases of castleman disease at low risk for HIV infection [J]. Am J Clin Pathol, 2002; 117(2): 268275.
- 37. Matsuyama M, Suzuki T, Tsuboi H, et al. Antiinterleukin6 receptor antibody (tocilizumab) treatment of multicentric Castleman’s disease [J]. Intern Med, 2007; 46(11): 771774.
- 38. Scott D, Cabral L, Harrington WJ Jr. Treatment of HIVassociated multicentric Castleman’s disease with oral etoposide [J]. Am J Hematol, 2001; 66(2): 148150.
- 39. Kumari P, Schechter GP, Saini N, et al. Successful treatment of human immunodeficiency virusrelated Castleman’s disease with interferonα [J]. Clin Infect Dis, 2000; 31(2): 602604.